Pattern of Inflammatory Markers and Use of Antibiotics in Meconium Aspiration Syndrome: A Retrospective Cohort Study

Uvaraj Periasamy1, Agnes Salvador2, Michael Janeczko2

  • 1Anesthesiology and Critical Care, Boston Children's Hospital, Boston, USA.

Cureus
|October 10, 2023
PubMed

Insights

Inflammatory markers like CRP in meconium aspiration syndrome (MAS) peak within 48 hours of life. However, these markers poorly correlate with illness severity or blood cultures, suggesting caution in using them for antibiotic decisions.

Area of Science:

  • Neonatal Medicine
  • Pediatric Pulmonology
  • Clinical Pathology

Background:

  • Meconium aspiration syndrome (MAS) is a significant cause of neonatal respiratory distress.
  • Understanding the inflammatory response in MAS is crucial for management.
  • Current guidelines for antibiotic use in MAS require further investigation regarding inflammatory markers.

Purpose of the Study:

  • To investigate the temporal patterns of inflammatory markers in neonates with MAS.
  • To assess the correlation between these inflammatory markers and the severity of illness.
  • To evaluate the relationship between inflammatory markers and antibiotic usage in MAS.

Main Methods:

  • Retrospective analysis of 76 neonates admitted with MAS.
  • Measurement of inflammatory markers including White Cell Count (WCC), Absolute Neutrophil Count (ANC), Immature to Total Neutrophil (I/T) ratio, and C-reactive protein (CRP).
  • Correlation analysis with illness severity scores (e.g., SNAPPE-II) and antibiotic duration.

Main Results:

  • WCC, ANC, and I/T ratio peaked at 12 hours of life (HOL); CRP peaked at 48 HOL.
  • Lower CRP levels at 12 and 24 HOL were observed in neonates requiring nasal cannula oxygen.
  • High CRP at 24 HOL correlated with longer antibiotic duration but not with blood cultures or SNAPPE-II score.

Conclusions:

  • MAS is characterized by a distinct pattern of inflammatory marker elevation within the first 48 HOL.
  • Inflammatory markers show a poor correlation with illness severity (SNAPPE-II) and blood culture results.
  • Antibiotic therapy decisions in MAS should not solely rely on inflammatory marker levels due to their limited predictive value for severity and infection.